These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 17376129)

  • 21. Guillain-Barre syndrome: a clinical study in King Chulalongkorn Memorial Hospital.
    Areeyapinan P; Phanthumchinda K
    J Med Assoc Thai; 2010 Oct; 93(10):1150-5. PubMed ID: 20973317
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Guillain Barré syndrome in pediatrics].
    Erazo Torricelli R
    Medicina (B Aires); 2009; 69(1 Pt 1):84-91. PubMed ID: 19240005
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunotherapy for Guillain-Barré syndrome in the US hospitals.
    Alshekhlee A; Hussain Z; Sultan B; Katirji B
    J Clin Neuromuscul Dis; 2008 Sep; 10(1):4-10. PubMed ID: 18772694
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Follow-up study on the clinical characteristics and treatment effect of the different types of Guillain-Barré syndrome in children].
    Wang XH; Zou LP; Wu HS; Fang F; Lü JL; Xiao J; Ding CH; Chen CH; Wang X; Jin H; Zhou WM; Cai FY
    Zhonghua Er Ke Za Zhi; 2011 Aug; 49(8):583-8. PubMed ID: 22093419
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Guillain-Barré syndrome.
    Fujimura H
    Handb Clin Neurol; 2013; 115():383-402. PubMed ID: 23931791
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barré syndrome.
    Kuitwaard K; de Gelder J; Tio-Gillen AP; Hop WC; van Gelder T; van Toorenenbergen AW; van Doorn PA; Jacobs BC
    Ann Neurol; 2009 Nov; 66(5):597-603. PubMed ID: 19938102
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Combination therapy with methylprednisolone (mPSL) and high-dose immunoglobulin (IVIg)].
    Nishida H; Kuroda T; Wakita K
    Nihon Rinsho; 2008 Jun; 66(6):1190-4. PubMed ID: 18540369
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinico-electrophysiological profile and predictors of functional outcome in Guillain-Barre syndrome (GBS).
    Verma R; Chaudhari TS; Raut TP; Garg RK
    J Neurol Sci; 2013 Dec; 335(1-2):105-11. PubMed ID: 24064258
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical profile of Guillain Barre syndrome.
    Dhadke SV; Dhadke VN; Bangar SS; Korade MB
    J Assoc Physicians India; 2013 Mar; 61(3):168-72. PubMed ID: 24475678
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical features and real-world outcomes of Guillain-Barré syndrome in the Philippines.
    I Espiritu A; Separa KJNJ; Milla FJC; Adiao KJB; Leochico CFD; Jamora RDG
    Neurol Res; 2021 Dec; 43(12):995-1004. PubMed ID: 34229572
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Guillain-Barre syndrome and its frontiers].
    Azulay JP; Verschueren A; Attarian S; Pouget J
    Rev Neurol (Paris); 2002 Dec; 158(12 Pt 2):S21-6. PubMed ID: 12690657
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Guillain-barré syndrome in pregnancy: early diagnosis and treatment is essential for a favorable outcome.
    Campos da Silva F; de Moraes Paula G; Dos Santos Esteves Automari CV; Mendes de Almeida DS; Ubirajara Cavalcanti Guimarães R
    Gynecol Obstet Invest; 2009; 67(4):236-7. PubMed ID: 19293590
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Guillain-Barre syndrome. Experience in a third level hospital].
    Téllez-Zenteno JF; Jacinto-Tinajero JC; Avila-Funes A; García-Ramos G; Negrete-Pulido O; Sentíes-Madrid H
    Rev Invest Clin; 2001; 53(4):311-4. PubMed ID: 11599477
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Guillain-Barré syndrome: subtypes and predictors of outcome from India.
    Kalita J; Misra UK; Goyal G; Das M
    J Peripher Nerv Syst; 2014 Mar; 19(1):36-43. PubMed ID: 24456386
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intravenous immunoglobulin treatment in children with Guillain-Barre syndrome.
    Gürses N; Uysal S; Cetinkaya F; Işlek I; Kalayci AG
    Scand J Infect Dis; 1995; 27(3):241-3. PubMed ID: 8539548
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Factors influencing outcome in Guillain-Barré Syndrome: comparison of plasma adsorption against other treatments.
    Seta T; Nagayama H; Katsura K; Hamamoto M; Araki T; Yokochi M; Utsumi K; Katayama Y
    Clin Neurol Neurosurg; 2005 Oct; 107(6):491-6. PubMed ID: 16202823
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasma exchange after initial intravenous immunoglobulin treatment in Guillain-Barré syndrome: critical reassessment of effectiveness and cost-efficiency.
    Oczko-Walker M; Manousakis G; Wang S; Malter JS; Waclawik AJ
    J Clin Neuromuscul Dis; 2010 Dec; 12(2):55-61. PubMed ID: 21386771
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacoeconomics of therapy for Guillain-Barré syndrome: plasma exchange and intravenous immunoglobulin.
    Tsai CP; Wang KC; Liu CY; Sheng WY; Lee TC
    J Clin Neurosci; 2007 Jul; 14(7):625-9. PubMed ID: 17532498
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Guillain-Barré syndrome in children treated with intravenous immunoglobulin].
    Andersen UM
    Ugeskr Laeger; 1993 Oct; 155(42):3392-4. PubMed ID: 8259633
    [TBL] [Abstract][Full Text] [Related]  

  • 40. How Different is AMAN from AIDP in Childhood GBS? A Prospective Study from North India.
    Gupta PK; Singhi P; Singhi S; Kasinathan A; Sankhyan N
    Indian J Pediatr; 2019 Apr; 86(4):329-334. PubMed ID: 30637680
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.